Clinical trial
Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1
NCT00546715 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- November 30, 2007
- Completion date
- May 31, 2008
- Enrollment
- 95 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis c